Nintedanib Heumann

Nintedanib, the active ingredient in Nintedanib Heumann, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is used to treat idiopathic pulmonary fibrosis, systemic sclerosis‑associated interstitial lung disease, and certain types of non‑small cell lung cancer in adult patients.

GNH USA supplies Nintedanib Heumann as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nintedanib is indicated for fibrotic lung disorders and selected oncologic indications.

- Idiopathic pulmonary fibrosis: slows decline in lung function and reduces disease progression. - Systemic sclerosis‑associated interstitial lung disease: improves lung capacity and delays worsening. - Non‑small cell lung cancer (in combination therapy): contributes to tumor growth inhibition and disease control.

Nintedanib may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of unease or urge to vomit. - Vomiting: expulsion of stomach contents. - Abdominal pain: discomfort in the stomach area. - Decreased appetite: reduced desire to eat. - Elevated liver enzymes: mild increases in ALT/AST.

Serious or Rare Side Effects: - Severe liver injury: jaundice, hepatitis, or hepatic failure. - Bleeding events: gastrointestinal or intracranial hemorrhage. - Arterial thromboembolism: clot formation in arteries. - Gastrointestinal perforation: hole in the stomach or intestines. - Severe infections: opportunistic or bacterial infections. - Hypertension: marked increase in blood pressure.

Before initiating therapy, clinicians should evaluate baseline health status and monitor for specific risks.

- Liver function monitoring: check ALT/AST regularly. - Bleeding risk assessment: avoid in patients with active hemorrhage. - Cardiovascular evaluation: monitor blood pressure and cardiac status. - Drug interaction review: assess concomitant medications that affect metabolism. - Pregnancy and lactation: safety not established; avoid unless benefit outweighs risk. - Store at room temperature: keep in the original container, protect from moisture and light.

Nintedanib can interact with other medicines, requiring attention to severity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nintedanib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may modestly raise plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy. - NSAIDs or antiplatelet agents: additive bleeding potential.